ID

34586

Descrizione

Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01257451

collegamento

https://clinicaltrials.gov/show/NCT01257451

Keywords

  1. 19/01/19 19/01/19 -
Titolare del copyright

see on clinicaltrials.gov

Caricato su

19 gennaio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Type 2 Diabetes Mellitus NCT01257451

Eligibility Type 2 Diabetes Mellitus NCT01257451

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
age: ≥ 70 years inclusive at visit 1.
Descrizione

ID.1

Tipo di dati

boolean

patients with a confirmed diagnosis of t2dm
Descrizione

ID.2

Tipo di dati

boolean

hba1c of ≥ 7% and ≤10.0% by central laboratory at visit 1 and assessed by the investigator to be inadequately controlled
Descrizione

ID.3

Tipo di dati

boolean

body mass index (bmi) in the range of 19-45kg/m2
Descrizione

ID.4

Tipo di dati

boolean

Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
fpg ≥ 270 mg/dl (≥ 15.0 mmol/l)
Descrizione

ID.5

Tipo di dati

boolean

previous or current participation in any vildagliptin clinical study.
Descrizione

ID.6

Tipo di dati

boolean

history of hypersensitivity to dpp-4 inhibitors.
Descrizione

ID.7

Tipo di dati

boolean

concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
Descrizione

ID.8

Tipo di dati

boolean

donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period other protocol-defined inclusion/exclusion criteria may apply
Descrizione

ID.9

Tipo di dati

boolean

Similar models

Eligibility Type 2 Diabetes Mellitus NCT01257451

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
age: ≥ 70 years inclusive at visit 1.
boolean
ID.2
Item
patients with a confirmed diagnosis of t2dm
boolean
ID.3
Item
hba1c of ≥ 7% and ≤10.0% by central laboratory at visit 1 and assessed by the investigator to be inadequately controlled
boolean
ID.4
Item
body mass index (bmi) in the range of 19-45kg/m2
boolean
Item Group
C0680251 (UMLS CUI)
ID.5
Item
fpg ≥ 270 mg/dl (≥ 15.0 mmol/l)
boolean
ID.6
Item
previous or current participation in any vildagliptin clinical study.
boolean
ID.7
Item
history of hypersensitivity to dpp-4 inhibitors.
boolean
ID.8
Item
concurrent medical condition that may interfere with the interpretation of efficacy and safety data during the study.
boolean
ID.9
Item
donation of blood or significant blood loss equaling to at least one unit of blood within the past 2 weeks of start of study or a blood transfusion within the past 12 weeks or planned regular transfusions during the study period other protocol-defined inclusion/exclusion criteria may apply
boolean

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial